sorafenib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702624
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Sorafenib is a first generation type II tyrosine kinase inhibitor with broad specificity for receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to sorafenib-mediated inhibition (Nguyen et al 2017; Linblad et al, 2017;reviewed in Kazi and Roonstrand, 2019).

Literature References
PubMed ID Title Journal Year
31066629 FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

Kazi, JU, Rönnstrand, L

Physiol. Rev. 2019
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Nguyen, B, Williams, AB, Young, DJ, Ma, H, Li, L, Levis, M, Brown, P, Small, D

Oncotarget 2017
26999641 Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Lindblad, O, Cordero, E, Puissant, A, Macaulay, L, Ramos, A, Kabir, NN, Sun, J, Vallon-Christersson, J, Haraldsson, K, Hemann, MT, Borg, A, Levander, F, Stegmaier, K, Pietras, K, Rönnstrand, L, Kazi, JU

Oncogene 2016
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!